Cadila Healthcare surges post USFDA nod for Gujarat facility
Avalokita Pandey / 16 Feb 2017
Cadila Healthcare, the Indian pharmaceutical company headquartered in Gujarat, said on Thursday that the US Food and Drug Administration (USFDA) has inspected and approved the company's Moraiya plant (Gujarat) for meeting all the manufacturing norms.
Cadila Healthcare, the Indian pharmaceutical company headquartered in Gujarat, said on Thursday that the US Food and Drug Administration (USFDA) has inspected and approved the company's Moraiya plant (Gujarat) for meeting all the manufacturing norms.
Analysts say that the development is positive for the company as no Form 483 was issued and this will not have any bearing on exports to the US, which is among the world's biggest drug markets. A Form 483 is issued when a violation is found against the USFDA regulations.
The stock of Cadila Healthcare was trading at Rs 420.10 on Thursday afternoon, up 17.33 per cent from its previous close. The shares staged a swift rally, surging 22.23 per cent to hit a high of Rs 438, and witnessed sustained buying post the company's announcement on the USFDA approval.
If you want to stay updated with the share market news today, keep a close watch on the indian stock market today with real time movements like sensex today live and overall stock market today trends. Investors tracking ipo allotment status, ipo news today, or the latest ipo india can also follow daily updates along with bse share price live data. Whether you are learning how to invest in stock market in india, preparing for a market crash today, or searching for the best stocks to buy in india, insights on top gainers today india, top losers today india, trending stocks india and long term stocks india help in making informed investment decisions.